Document:

EX-10.3

 Exhibit 10.3 
 SETTLEMENT AGREEMENT AND MUTUAL RELEASES 

      This Settlement Agreement and Mutual Releases (“Agreement”) is made on this
28th day of June 2012 (the “Effective Date”) by and between CryoLife, Inc. (“CryoLife”), a Florida corporation, and Medafor, Inc. (“Medafor”), a Minnesota corporation (collectively the “Parties”). 

RECITALS: 
       WHEREAS, the Parties are involved in litigation pending in the United States District Court for the Northern District of Georgia, styled CryoLife, Inc. v. Medafor,
Inc., Civil Action No. 1:09-cv-1150 (the “Litigation”); 

      WHEREAS, the Parties desire to settle all claims between them, including all claims
and counterclaims asserted or that might have been asserted in the Litigation except as expressly described herein, without admission of liability or fault by any of them, on the terms and conditions as hereinafter set forth, thereby avoiding the
burdens, risks and expenses of further court litigation and/or administrative action; 

      NOW, THEREFORE, in consideration of the mutual releases and other promises,
obligations, agreements and covenants made hereunder and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 

 

	1.	 Settlement Payments to CryoLife 

      Medafor shall pay to CryoLife the total amount of Three Million Five Hundred Thousand
Dollars ($3,500,000) according to the following schedule: 
  

	 	(a)	 $1,750,000 on or before Monday, July 9, 2012; and 

 

	 	(b)	 $1,750,000 on or before Thursday, September 6, 2012. 

The payments described above shall be delivered to CryoLife via wire transfer pursuant reasonable instructions to be provided by
CryoLife. 
  

	2.	 Mutual Releases 

       a.        CryoLife, for itself, its officers, directors, successors and assigns, employees, and agents, does hereby
release, remise, acquit, and forever discharge Medafor and its officers, directors, employees, agents, and attorneys, of and from any and all actions, causes of action, claims, suits, demands, rights, damages, losses, costs, expenses, fees,
accounts, judgments, executions, debts, obligations, and any and all other liabilities of any kind or nature whatsoever either in law or in equity whether known or unknown, suspected or unsuspected that CryoLife, to the date of this Agreement, ever
had or now has against Medafor. 

      b.         Except as expressly
provided below, Medafor, for itself, its officers, directors, successors and assigns, employees, and agents, does hereby release, remise, acquit and forever discharge CryoLife and its officers, directors, employees, agents, and attorneys of and from
any and all actions, causes of action, claims, suits, demands, rights, damages, losses, costs, expenses, fees, accounts, judgments, executions, debts, obligations, and any and all other liabilities of any kind or nature whatsoever either in law or
in equity whether known or unknown, suspected or unsuspected that Medafor, to the date of this Agreement, ever had or now has against CryoLife. 
 Notwithstanding the mutual releases described above, Medafor does not release and expressly reserves any and all claims relating to patent rights related to: (1) United States patent number
6,060,461; (2) all patents or patent applications claiming priority to the file date of United States patent number 6,060,461; and (3) all foreign counterparts, reissues, reexaminations, extensions, continuations, continuations in part,
continuing prosecution applications, and divisions of United States patent number 6,060,461. 
  

	3.	 Mutual Dismissal of Claims/Counterclaims 

      Both Parties agree to have their attorneys execute and file with the appropriate
court a mutual dismissal with prejudice of any and all claims and counterclaims asserted in this Litigation, in the form of the Mutual Dismissal with Prejudice attached hereto as Exhibit A. The Parties agree and acknowledge that the Court is to
retain jurisdiction of this matter for the purpose of enforcing this binding settlement. 
  

	4.	 Notice; Recipients of Payments 

      All notices contemplated by this Agreement shall be sent to the following addressees:

       If to CryoLife, Inc.: 

Jeff W. Burris, Esq. 
 Vice President and General Counsel 
 CryoLife, Inc. 

1655 Roberts Blvd., N.W. 
 Kennesaw, Georgia 30144 
 and 

Henry R. Chalmers, Esq. 
 Arnall Golden Gregory LLP 
 171 17th Street, N.W., Suite 2100 

Atlanta, Georgia 30363 

       If to Medafor, Inc.: 

Mr. Gary J. Shope 
 Chief Executive Officer 
 Medafor, Inc. 

2700 Freeway Boulevard 
 Suite 800 
 Minneapolis, Minnesota 55430 

and 
 Lisa L. Heller, Esq. 
 Robins, Kaplan, Miller & Ciresi
LLP 
 One Atlantic Center 

1201 West Peachtree Street, Suite 2200 

Atlanta, Georgia 30300 
  

	5.	 Attorneys’ Fees and Costs.  

      The Parties agree and acknowledge that each shall bear its own costs and expenses,
including attorneys’ fees and filing fees, incurred in or as a result of the Litigation. 
  

	6.	 Capacity to Execute. 

       Each Party represents and warrants that it has the full right, power, capacity and authority to execute this Agreement and to consummate the transactions contemplated
hereby, and that this Agreement has been duly executed by it so as to constitute its legal, valid, and binding obligation in accordance with its terms. 
  

	7.	 No Assignment. 

       The Parties represent and warrant that they hold all claims or causes of action that are covered by the mutual releases set forth above, including, but not limited to,
any and all claims or causes of action that were asserted, or could have been asserted, in the Litigation, and that they have not sold, transferred or otherwise conveyed any of such claims or rights (including the power or authority to bring such
claims in its name, as its representative, or otherwise) against the other Party to any other person or entity. 
  

	8.	 Incorporation of the Parties’ Stipulated Protective Order. 

      The Parties agree to negotiate a proposed amendment to the Stipulated Protective
Order to address the retention and destruction of documents subject thereto. 

	9.	 Entire Agreement. 

       This Agreement constitutes the entire agreement of the Parties. This Agreement cannot be modified, supplemented, or amended unless agreed in advance, in writing, by all
of the Parties. 
  

	10.	 Construction. 

       The Parties and their counsel participated in the negotiation and drafting of this Agreement. If any ambiguity or question of intent or interpretation arises, the
Parties intend that (a) this Agreement be construed as if they had drafted it together, and (b) no presumption or burden of proof arises favoring or disfavoring any party by virtue of its role in drafting any provision of this Agreement.

  

	11.	 Binding Effect. 

       This Agreement shall be binding upon and inure to the benefit of the Parties, their successors, affiliates, licensees and assigns. 

 

	12.	 Waiver. 

       Waiver by any Party of any breach or failure by another Party to enforce the terms and conditions of this Agreement, at any time, shall not in any way effect, limit, or
waive the right of that Party thereafter to enforce or compel strict compliance with any term or condition thereof. 
  

	13.	 Governing Law. 

       This Agreement is made and entered into in the State of Georgia and shall, in all respects, be interpreted, enforced and governed under the laws of the State of
Georgia. 
  

	14.	 Representation by Legal Counsel.  

      The undersigned represent and agree that they have discussed all aspects of this
Agreement with their respective attorneys and that they have carefully read and fully understand all of the provisions of this Agreement and that it is entered into voluntarily for the purposes of making full and final compromise settlement of any
and all claims, disputed or otherwise, on account of the matters set out hereinabove; that, in entering into this settlement and in executing this Agreement, they have taken into consideration all past, present and future losses, damages, expenses,
and consequences; that, except as set forth in Paragraph 2.b above, this Agreement shall apply to all such losses, damages, expenses, and consequences; and that this settlement is made and this Agreement executed to terminate and forever foreclose
said alleged claims made by the undersigned and their subrogees, successors, and assigns as a result of the matters set out herein. 

	15.	 Further Assurances. 

       The Parties agree to execute such other documents as may be reasonably necessary to carry out the intent and purpose of this Agreement. 

 

	16.	 Headings. 

       The headings that have been used to designate the various sections of this Agreement are solely for convenience in reading and for ease of reference and shall not be
construed in any event or manner as interpretive of this Agreement. 
  

	17.	 Counterparts. 

       This Agreement may be executed in two (2) counterparts, each of which shall be deemed to be an original and all of which shall constitute one and the same
instrument. 
       IN WITNESS WHEREOF, the Parties have caused this instrument
to be duly executed and delivered as of the Effective Date. 
 Accepted and agreed by the Parties: 

 

									
	 CryoLife, Inc.
	 		 	 Sworn to and subscribed before
	 	
		 		 		 	 me this  25th  day of  June , 2012.
	 	
	   /s/ Steven G. Anderson
	 		 		 	
	 By:  Steven G. Anderson
	 		 	   /s/ Suzanne K Gabbert
	 	
	 Its:  CEO, Chairman and President
	 		 	 Notary Public
	 	
	 Date:
	 	         6-25-12
	 		 		 	
		 		 		 	 My Commission Expires:
	 	
					
		 		 		 	 [ Notarial Seal ]
	 	
				
	 Medafor, Inc.
	 		 	 Sworn to and subscribed before
	 	
		 		 		 	 me this  28th  day of  June , 2012.
	 	
	   /s/ Gary J. Shope
	 		 		 	
	 By: Gary J. Shope
	 		 	   /s/ Colleen Mary Law
	 	
	 Its:  CEO
	 		 	 Notary Public
	 	
	 Date:
	 	     June 28, 2012
	 		 		 	
		 		 		 	 My Commission Expires: 1/31/13
	 	
					
		 		 		 	 [ Notarial Seal ]
	 	

 EXHIBIT A 

UNITED STATES DISTRICT COURT FOR THE 
 NORTHERN DISTRICT OF GEORGIA 
 ATLANTA DIVISION 

 

					
	 CRYOLIFE, INC.,
	  	 )
	    	
		  	 )
	    	
	 Plaintiff,
	  	 )
	    	
		  	 )
	    	 CIVIL ACTION NO.

	 v.
	  	 )
	    	
		  	 )
	    	 1:09-CV-1150-AT

	 MEDAFOR, INC.,
	  	 )
	    	
		  	 )
	    	
	 Defendant.
	  	 )
	    	
	  
	  	 )
	    	

 STIPULATED DISMISSALS WITH PREJUDICE 

COME NOW, Plaintiff CryoLife, Inc. (“CryoLife”) and Defendant Medafor, Inc. (“Medafor”), and,
pursuant to Rule 41(a)(1)(ii) of the Federal Rules of Civil Procedure, hereby stipulate that the above cause be dismissed with prejudice with regard to all claims and counterclaims that have been raised between the parties to this lawsuit, and that
each party will bear its own costs and attorneys’ fees. The Parties further agree that this Court will retain jurisdiction of this matter solely for the purpose of enforcing the terms of the Settlement Agreement. 

This the      day of June, 2012. 

 Respectfully Submitted By: 

 

					
	 ARNALL GOLDEN GREGORY LLP
	 		  	 ROBINS, KAPLAN, MILLER & CIRESI LLPEX-10.4

 Exhibit 10.4 
 SETTLEMENT AND RELEASE AGREEMENT 
 This Settlement and Release Agreement
(“Agreement”) is effective as of June 14th,
2012 (the “Effective Date”), by and between CardioFocus, Inc. (“CardioFocus” or a “Party”), a Massachusetts corporation, and Cardiogenesis Corporation (“Cardiogenesis” or a “Party”), a Florida
corporation. CardioFocus and Cardiogenesis are sometimes referred to hereinafter collectively as the “Parties.” 
  

	1.	 Background of the Agreement 

 1.1.        CardioFocus and Cardiogenesis are parties to the civil action captioned CardioFocus, Inc. v. Candela Corporation, et al., Case No.:
08-CV-10285NMG, pending in the United States District Court Massachusetts (hereinafter, “the Litigation”). 
 1.2.        The Parties wish to compromise and settle the Litigation and to fully and finally release and forever discharge each other of all possible claims on the
terms and conditions stated herein. 
 1.3.        This Agreement sets
forth Cardiogenesis’ entire liability, if any, and CardioFocus’ sole and exclusive remedy in connection with the Litigation. 
 1.4.        The Parties enter into the Agreement in consideration of the mutual covenants and promises set forth herein. 

 

	2.	 Definitions 

 2.1.        In addition to the terms defined elsewhere herein, each of the following terms shall have the meaning set forth below: 

2.1.1.   “CardioFocus Patents in Suit” means United States Patent Nos. 6,547,780
(“the‘780 patent”), 6,159,203 (“the‘203 Patent”) and 5,843,073 (“the ‘073 

  
 1 

 
patent”) and all continuations, continuations-in-part, divisionals, reissues, and reexamination certificates of the ‘780, ‘203 and ‘073 patents, and including any counterparts
thereof in any country of the world in which there are counterparts of the ‘780, ‘203 and ‘073 patents. 
 2.1.2.   “Accused Products” means the Cardiogenesis TMR 2000, Solargen 2100, SoloGrip III, Pearl 5.0 and Pearl 8.0. 

2.1.3.   “Parents” with respect to Cardiogenesis means, at any time, any person or entity,
whether previously, now or hereafter existing, which directly or indirectly owns or controls at least fifty percent (50%) of Cardiogenesis’ outstanding shares, securities or ownership interest (representing the right to vote for the
election of directors or other managing authority), or which directly or indirectly owns or controls the maximum percentage permitted under local laws or regulations in those countries where fifty percent (50%) ownership or control by a foreign
entity is not permitted. “Parents” with respect to CardioFocus means, at any time, any person or entity, whether previously, now or hereafter existing, which directly or indirectly owns or controls at least fifty percent (50%) of
CardioFocus’ outstanding shares, securities or ownership interest (representing the right to vote for the election of directors or other managing authority), or which directly or indirectly owns or controls the maximum percentage permitted
under local laws or regulations in those countries where fifty percent (50%) ownership or control by a foreign entity is not permitted. 
 2.1.4.   “Subsidiaries” with respect to Cardiogenesis means, at any time, whether previously, now or hereafter existing, any person or entity at least fifty percent (50%), or the
maximum percentage permitted under local laws or regulations in those countries where fifty percent (50%) ownership by a foreign entity is not permitted, of whose outstanding shares, securities or ownership interest (representing the right to
vote for the election of directors or other managing authority) are directly or indirectly owned or controlled by Cardiogenesis. 

  
 2 

 
“Subsidiaries” with respect to CardioFocus means, at any time, whether previously, now or hereafter existing, any person or entity at least fifty percent (50%), or the maximum
percentage permitted under local laws or regulations in those countries where fifty percent (50%) ownership by a foreign entity is not permitted, of whose outstanding shares, securities or ownership interest (representing the right to vote for
the election of directors or other managing authority) are directly or indirectly owned or controlled by CardioFocus. 
 2.1.5.   “Affiliates” with respect to Cardiogenesis means, at any time, whether previously, now or hereafter existing, any person or entity at least fifty percent (50%), or the
maximum percentage permitted under local laws or regulations in those countries where fifty percent (50%) ownership by a foreign entity is not permitted, of whose outstanding shares, securities or ownership interest (representing the right to
vote for the election of directors or other managing authority) are directly or indirectly owned or controlled by any of Cardiogenesis’ Parents or Subsidiaries. “Affiliates” with respect to CardioFocus means, at any time, whether
previously, now or hereafter existing, any person or entity at least fifty percent (50%), or the maximum percentage permitted under local laws or regulations in those countries where fifty percent (50%) ownership by a foreign entity is not
permitted, of whose outstanding shares, securities or ownership interest (representing the right to vote for the election of directors or other managing authority) are directly or indirectly owned or controlled by any of CardioFocus’ Parents or
Subsidiaries. 
  

	3.	 Payment by Cardiogenesis 

 3.1.        Within thirty (30) days of execution of the Agreement by all Parties, Cardiogenesis will pay the sum of Four Million Five Hundred Thousand Dollars
($4,500,000.00 U.S.) to CardioFocus and its attorneys, Niro, Haller & Niro, by wire transfer to a client account provided by Niro, Haller & Niro. 

  
 3 

 3.2.      The Parties acknowledge and agree
that all conditions precedent for the payment obligation set forth in paragraph 3.1 above have been fully satisfied, and such payment obligation cannot hereafter be forfeited, extinguished, or rendered null and void for any reason, including but not
limited to a subsequent finding of invalidity, unenforceability, or non-infringement of the CardioFocus Patents in Suit. The Parties further acknowledge and agree that Cardiogenesis’ failure to make the payment pursuant to paragraph 3.1 above
shall constitute a material breach of the provisions of this Agreement, and shall render null and void the releases and covenants granted in this Agreement. 
  

	4.	 Releases 

 4.1.      CardioFocus and its officers, directors, managers, shareholders, employees, agents, principals, successors, assigns, representatives, insurers, and attorneys
knowingly, voluntarily, unconditionally, fully and finally release, acquit, and forever discharge Cardiogenesis, its Subsidiaries, all Affiliates of Cardiogenesis and its Subsidiaries, and all Parents of Cardiogenesis and its Subsidiaries, and all
officers, directors, managers, shareholders, employees, agents, principals, successors, assigns, representatives, insurers, and attorneys of any of the foregoing, and all purchasers, distributors, sellers, manufacturers, importers, and users of the
Accused Products of and from any and all claims, actions, causes of action, demands, suits, liabilities, damages, losses, costs and expenses of any and every kind and nature whatsoever, whether known or unknown, actual or potential, suspected or
unsuspected, fixed or contingent (collectively, “Claims”), which Claims have been made as of the date of this Agreement, or which might be made at any time in the future, that arise out of, or relate to, directly or indirectly, the
CardioFocus 

  
 4 

 
Patents in Suit as defined in paragraph 2.1.1 above and/or the Accused Products as defined in paragraph 2.1.2 above, including, but not limited to: (a) any Claims related to alleged
infringement, inducement of infringement, or contributory infringement of any of the claims of the CardioFocus Patents in Suit, as defined in paragraph 2.1.1 above; (b) any Claims that the Accused Products, as defined in paragraph 2.1.2 above,
infringe any valid claim of any patent that is currently owned by CardioFocus, including all parents, continuations, continuations-in-part, divisionals, reissues, and reexamination certificates and foreign counterparts; and (c) any Claims which
by pleading, amendment, or supplement were or could be or could have been alleged in the Litigation, provided, however, that nothing in this paragraph shall be construed to release, acquit, or discharge Cardiogenesis from any obligation it has
expressly assumed in the Agreement. 
 4.2.        Cardiogenesis and its
officers, directors, managers, shareholders, employees, agents, principals, successors, assigns, representatives, insurers, and attorneys knowingly, voluntarily, unconditionally, fully and finally release, acquit, and forever discharge CardioFocus,
its Subsidiaries, all Affiliates of CardioFocus and its Subsidiaries, and all Parents of CardioFocus and its Subsidiaries, and all officers, directors, managers, shareholders, employees, agents, principals, successors, assigns, representatives,
insurers, and attorneys of any of the foregoing, of and from any and all claims, actions, causes of action, demands, suits, liabilities, damages, losses, costs and expenses of any and every kind and nature whatsoever, whether known or unknown,
actual or potential, suspected or unsuspected, fixed or contingent (collectively, “Claims”), which Claims have been made as of the date of this Agreement, or which might be made at any time in the future, that

  
 5 

 
arise out of, or relate to, directly or indirectly, the CardioFocus Patents in Suit as defined in paragraph 2.1.1 above, including, but not limited to: (a) any Claims related to alleged
invalidity, inequitable conduct, or misuse of any of the claims of the CardioFocus Patents in Suit as defined in paragraph 2.1.1 above, and (b) any Claims which by pleading, amendment, or supplement were or could be or could have been alleged
in the Litigation, provided, however, that nothing in this paragraph shall be construed to release, acquit, or discharge CardioFocus from any obligation it has expressly assumed in the Agreement. 

 

	5.	 Dismissal of Litigation 

 5.1.        Promptly upon the execution of this Agreement by both Parties, counsel for the Parties shall cause to be filed in the Litigation a Final Order and
Dismissal with Prejudice of all of CardioFocus’ claims against Cardiogenesis and all of Cardiogenesis’ claims against CardioFocus. 
 5.2.        Each Party will pay its own attorneys’ fees and costs incurred in connection with the Litigation. 

5.3.        Each Party agrees that this Agreement does not constitute evidence
of, or any admission of any liability, omission, or wrongdoing of any kind, and it shall not be offered or received into evidence or otherwise filed or lodged in any proceeding against any Party except as maybe necessary to prove and enforce its
terms. It is expressly understood and agreed that neither this Agreement nor any consideration provided pursuant to the Agreement are to be construed as an admission of liability on the part of Cardiogenesis or any related entity. This Agreement
represents a settlement and compromise and is not intended to be a recognition of either the validity, enforceability or 

  
 6 

 
infringement of the CardioFocus Patents in Suit and is a compromise and settlement under Rule 408 of the Federal Rules of Evidence and shall not be introduced into evidence by either party except
in connection with a claim of breach of this Agreement. 
  

	6.	 Entire Agreement and Amendments 

 6.1.        The Agreement constitutes the entire agreement of the Parties with respect to the subject matter hereof and supersedes all prior representations,
discussions, negotiations, agreements, and understandings, whether written or oral, with respect thereto. 

6.2.        The Agreement may be modified only by a written amendment signed by
all Parties, and no waiver of any provision of the Agreement or the breach thereof shall be effective unless expressed in a writing signed by the waiving party. The waiver by any party hereto of any of the provisions of the Agreement or of the
breach thereof shall not operate or be construed as a waiver of any other provision or breach thereof. 
  

	7.	 Assignment and Transfer 

 7.1.        The covenants and releases granted herein by CardioFocus to Cardiogenesis are personal and are non-transferable by Cardiogenesis to a third party
without CardioFocus’ express written consent, which shall not be unreasonably withheld, except the rights of Cardiogenesis may be transferred or assigned to (1) another entity in connection with a reorganization, merger, consolidation,
acquisition or other restructuring involving all or substantially all of the voting securities and/or assets of Cardiogenesis; or (2) any successor entity or entities that acquire all or any part of Cardiogenesis’ applicable business(es)
to which the CardioFocus Patents in Suit as defined in paragraph 2.1.1 above may relate, provided that the transfer or assignment is limited to the past, present and future products and/or services of the transferred business(es) only and not to any
past, present, 

  
 7 

 
or future products and/or services of any acquiring company. In the event of any transfer or assignment, the covenants and releases granted to Cardiogenesis in this Agreement shall remain in full
force and effect and shall not be affected by such transfer or assignment. 
  

	8.	 Authority, Representations, and Warranties 

8.1.        The persons executing this Agreement represent and warrant that they
have read the agreement, have the authority to execute it on behalf of the Party for which they have signed and understand its contents and are executing it freely and voluntarily with an intent to bind their respective Party to its terms.

 8.2.        The Parties represent and warrant that they have the
authority, without joinder by others, to grant the releases and covenants provided for in this Agreement. The Parties further represent and warrant that they have not assigned or otherwise transferred, either in whole or in part, any claim released
in the Agreement, and that there are no outstanding agreements, assignments, or encumbrances inconsistent with the provisions of the releases and covenants provided for in this Agreement. 

8.3.        CardioFocus represents and warrants that it has sole ownership in the
CardioFocus Patents in Suit as defined in paragraph 2.1.1 above, and has the sole right to collect damages, including past damages for infringement, and has the sole right to grant the rights granted herein and to enter into this Agreement, and
shall defend, indemnify and hold harmless Cardiogenesis and its Parents, Subsidiaries and Affiliates from and against any claims from a third party claiming a right to payment of any portion of the settlement agreement, or for infringement of the
CardioFocus Patents in Suit. 

  
 8 

	9.	 Notice and Right to Cure 

 9.1.        In the event that a party (“Complaining Party”) considers that another party hereto (“Allegedly Breaching Party”) has breached a
term or provision of the Agreement, the Complaining Party shall give written notice to the Allegedly Breaching Party describing the nature of the breach in reasonable detail. The Allegedly Breaching Party shall then have ten (10) days to cure
the alleged breach to the reasonable satisfaction of the Complaining Party. 

9.2.        The provisions of paragraph 9.1 shall be followed by the Parties
prior to the initiation of any suit or legal proceeding relating to the Agreement, including any suit or legal proceeding to enforce the terms of the Agreement. 

9.3.        All notices, requests, or demands relating to the Agreement shall be
in writing and shall be deemed to have been adequately given and delivered (a) upon personal delivery (including personal delivery by overnight mail or courier) to the party to be notified, (b) five (5) business days after deposit
with certified mail, return receipt requested, prepaid and addressed to the party to be notified at the address set forth herein, or (c) immediately upon transmission and receipt of confirmation if sent by facsimile to the receiving party at
the facsimile number set forth herein. 
 9.4.        All notices,
requests, or demands hereunder shall be made to the following representatives of the Parties at the address set forth below, unless another address is specified hereafter in writing by a Party: 

9.4.1.    If to Cardiogenesis: 

Jeff Burris 
 Vice President & General Counsel 
 CryoLife 

1655 Roberts Boulevard, N.W. 
 Kennesaw, Georgia 30144 

  
 9 

 with a copy to: 

Bart L. Kessel 
 Tucker Ellis LLP 
 515 South Flower Street 

42nd Floor 
 Los Angeles, California 90071 
 9.4.2.    If
to CardioFocus: 
 Steve Sagon 

Chief Executive Officer 
 CardioFocus, Inc. 
 500 Nickerson Rd. 

Marlborough, Massachusetts 01752 

with a copy to: 
 Gregory P. Casimer 
 Frederick C. Laney 

Niro, Haller & Niro 
 181 West Madison Street, Suite 4600 
 Chicago, Illinois 60602

  

	10.	 General 

 10.1.    This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and all of which counterparts taken
together shall constitute one and the same instrument. Facsimile and electronically scanned signatures shall be deemed original signatures. It shall not be necessary in making proof of this document or any counterpart hereof to produce or account
for any of the other counterparts. 
 10.2.    The Parties agree not to make any public
statements that defame or disparage the business reputation, practices or conduct of the other party, its directors or officers. 

  
 10 

 10.3.    Each of the Parties agrees, promptly upon
reasonable request therefore, to prepare, execute, acknowledge, deliver, or file such other an further papers, forms, instruments, and documents, and to take such other and further action as may be necessary or convenient to evidence, perfect, or
enforce any of the rights and obligations arising under or in connection with the Agreement or with any document or agreement referred to herein or otherwise to consummate or carry out the intent of the Agreement. 

10.4.    The section headings contained in the Agreement are for convenience only and shall not in
any way affect the meaning or interpretation of the provisions hereof. 
 10.5.    In the
event of litigation relating to this Agreement, if a court of competent jurisdiction determines that a Party has breached the Agreement, then the breaching Party shall be liable and shall pay to the other Party the legal fees incurred by the other
Party in connection with such litigation, including any appeal therefrom 
 This Agreement was jointly drafted
by the Parties and the language of all parts of the Agreement shall in all cases be construed as a whole according to its meaning and not strictly for or against any of the Parties. 

  
 11 

 IN WITNESS WHEREOF, the Parties have hereunto signed their names on the
dates indicated. 
  

											
	   CARDIOFOCUS, INCORPORATED
	 		 	 CARDIOGENESIS CORPORATION

				
	  /s/ Stephen W. Sagon
	 		 	  /s/ D. A. Lee
	 	
						
	 Dated:
	 	  June 14, 2012
	 		 	 Dated:
	 	
            6/14/2012
	 	

											
						
	 Its:
	 	      President & CEO
	 		 	 Its:
	 	      EVP, COO & CFO
	 	

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]